

Biological Chemistry of Arsenic, Antimony and Bismuth

Editor

HONGZHE SUN

*Department of Chemistry, University of Hong Kong,
P. R. China*



A John Wiley and Sons, Ltd, Publication

Contents

<i>List of Contributors</i>	<i>xiii</i>
<i>Preface</i>	<i>xv</i>
1 The Chemistry of Arsenic, Antimony and Bismuth	1
<i>Neil Burford, Yuen-ying Carpenter, Eamonn Conrad and Cheryl D.L. Saunders</i>	
1.1 Properties of the Elements	1
1.2 Allotropes	3
1.3 Bond Energies	4
1.4 Oxidation States	4
1.5 Relativistic Effects and Orbital Contraction	5
1.6 Structure and Bonding	6
1.7 Clusters and Extended Structures	9
1.8 Hybridization and Inversion	11
1.9 Coordination Chemistry	12
1.10 Geological Occurrence	14
1.11 Aqueous Chemistry and Speciation	14
1.12 Analytical Methods and Characterization	15
1.13 Conclusions	15
References	15
2 Arsenic's Interactions with Macromolecules and its Relationship to Carcinogenesis	19
<i>Kirk T. Kitchin</i>	
2.1 Introduction	19
2.2 Arsenic's Interactions with DNA and Proteins	20
2.2.1 Release of Zinc from Zinc Finger Proteins has been Chemically Demonstrated	26
2.2.2 Binding of Trivalent Arsenic to Zinc Finger Proteins	26
2.2.3 Reduced Function of Zinc Finger Proteins	27
2.2.4 Restoration of Zinc Finger Protein Function	27
2.3 Cancer – MOA	30
2.3.1 Binding to RSH Groups	30
2.3.2 Cancer – MOA – Oxidative Stress	31
2.3.3 Cancer – MOA – DNA Methylation	33

2.4	Arsenic's Many Connections to Carcinogenesis	34
2.4.1	Human Carcinogenicity	34
2.4.2	Animal Studies - Promotion of Carcinogenesis	38
2.4.3	Animal Studies - Complete Carcinogenesis	38
2.4.4	Arsenicals in the Treatment of Leukaemia - APL	40
2.5	Sources of Information on Arsenic's Mode of Action, Biochemical Effects, Carcinogenesis in Animals and Man, Metabolism and Analytical Chemistry	40
2.6	Conclusion	46
	Acknowledgements	46
	Disclaimer	46
	Abbreviations	47
	References	48
3	Biological Chemistry of Antimony and Bismuth	53
	<i>Nan Yang and Hongzhe Sun</i>	
3.1	Introduction	53
3.2	Biorelevant Coordination Chemistry of Antimony and Bismuth	53
3.3	Antimony and Bismuth Compounds in Medicine	54
3.3.1	Antimony in Medicine	54
3.3.2	Bismuth in Medicine	55
3.4	Interaction with Nucleic Acids	56
3.4.1	Interaction of Antimony with Nucleosides and Nucleotides	56
3.4.2	Interaction of Bismuth with Nucleosides and Nucleotides	58
3.5	Interaction with Amino Acids and Peptides	58
3.5.1	Interaction of Antimony with Amino Acids and Peptides	58
3.5.2	Interaction of Bismuth with Amino Acids and Peptides	61
3.6	Interaction with Proteins and Enzymes	62
3.6.1	Interaction of Antimony with Proteins and Enzymes	62
3.6.2	Interaction of Bismuth with Proteins and Enzymes	68
3.7	Conclusion and Perspectives	77
	Acknowledgements	77
	References	77
4	Metallomics Research Related to Arsenic	83
	<i>Hiroki Haraguchi</i>	
4.1	Metallomics – Integrated Biometal Science	83
4.2	Analytical Feasibility of ICP-AES and ICP-MS	85
4.3	Chemical Speciation of Trace Elements in Biological Samples	87
4.3.1	Speciation of Arsenic in Salmon Egg Cells	89
4.3.2	Speciation of Arsenic Species in Human Urine	93
4.3.3	Speciation of Arsenic Species in Human Blood Serum	96
4.3.4	Arsenic Metabolism in Hamsters and Rats after an Oral Dose of Arsenite	98

4.3.5	Animal Species Difference in the Uptake of Dimethylated Arsenic by Red Blood Cells	103
4.3.6	Speciation and Excretion Patterns of Arsenic Metabolites in Human Urine after Ingestion of Edible Seaweed, Hijiki	105
4.4	Summary	109
	Acknowledgements	110
	References	110
5	Arsenic in Traditional Chinese Medicine	113
	<i>Kui Wang, Siwang Yu and Tianlan Zhang</i>	
5.1	Arsenic Bearing Minerals and their Clinical Applications	113
5.1.1	Introduction	113
5.1.2	Arsenolite and its Clinical Applications in Traditional Chinese Medicine (TCM)	115
5.1.3	Realgar and Orpiment and their Clinical Applications in TCM	116
5.1.4	Processing of Arsenic Bearing Minerals	117
5.2	Metabolism and Pharmacokinetics of Arsenic Bearing Minerals	119
5.2.1	Arsenolite and Arsenic Trioxide	119
5.2.2	Metabolism and Pharmacokinetics of Realgar and Orpiment	121
5.2.3	Nanoparticles of Realgar	122
5.3	Pharmacological Activities and Mechanisms of Actions of ABMs	122
5.3.1	Mechanisms of Anticancer Action of Arsenolite and ATO	122
5.3.2	Mechanisms of Anticancer Actions of Realgar	125
5.3.3	Arsenolite on Asthma Prevention	127
5.3.4	Realgar on Brain Protection	128
5.4	Perspectives	128
	References	130
6	Microbial Transformations of Arsenic in Aquifers	135
	<i>Jonathan R. Lloyd</i>	
6.1	An Introduction to the Microbial Cycling of Arsenic	135
6.2	The Biochemistry of Microbial Arsenic Transformations	137
6.2.1	Microbial Resistance to As(V) via the Arsenic Operon	137
6.2.2	Gaining Energy from Arsenic: the Dissimilatory Reduction of As(V) under Anaerobic Conditions	137
6.2.3	Closing the Arsenic Cycle: the Oxidation of As(III)	138
6.3	Microbially Driven Mobilization of Arsenic in Aquifers: a Humanitarian Disaster	139
6.3.1	Microbial Ecology of Arsenic Impacted Aquifers: Hunting for the Organisms that Mobilize Arsenic	140
6.4	Conclusions and Future Directions	141
	Acknowledgements	142
	References	142

7	Biomethylation of Arsenic, Antimony and Bismuth	145
	<i>Richard O. Jenkins</i>	
7.1	Introduction	145
7.2	Biomethylation of Arsenic	147
7.2.1	Microbial Biomethylation of Arsenic	147
7.2.2	Mammalian Biomethylation of Arsenic	150
7.2.3	Arsenic Biomethylation/Demethylation and Organoarsenic Compounds in the Environment	156
7.3	Biomethylation of Antimony	159
7.3.1	Organoantimony Compounds in the Environment	159
7.3.2	Antimony Biomethylation in Mammals	161
7.3.3	Antimony Biomethylation and its Relation to SIDS	161
7.3.4	Microbial Biomethylation of Antimony	162
7.3.5	Biological Mechanism of Antimony Biomethylation	168
7.3.6	Abiotic Reactions of Particular Relevance to Antimony Biomethylation Studies	169
7.4	Biomethylation of Bismuth	169
7.4.1	Organobismuth Compounds in the Environment	171
7.4.2	Microbial Biomethylation of Bismuth	171
7.4.3	Biological Mechanism of Bismuth Biomethylation	173
	Abbreviations	174
	References	175
8	Metalloid Transport Systems	181
	<i>Hsueh-Liang Fu, Xuan Jiang and Barry P. Rosen</i>	
8.1	Introduction	181
8.2	Metalloid Uptake Systems	183
8.2.1	Arsenate Uptake Systems	183
8.2.2	Uptake Systems for Arsenite and Antimonite	184
8.2.3	Boron Uptake Systems	191
8.2.4	Uptake Systems for Silicon and Germanium	193
8.3	Metalloid Efflux Systems	195
8.3.1	Eukaryotic MRP Efflux Pumps	195
8.3.2	ArsB	196
8.3.3	ArsA	197
8.3.4	Acr3	200
8.3.5	Efflux Systems for Silicon	201
8.3.6	Efflux Systems for Boron	202
8.4	Summary and Conclusions	202
	Acknowledgements	202
	References	203

9 Bismuth Complexes of Porphyrins and their Potential in Medical Applications	209
<i>Bernard Boitrel</i>	
9.1 Introduction	209
9.2 Early Work (1969-1994)	210
9.3 Bismuth Complexes of Unfunctionalized Porphyrins	211
9.3.1 The First X-ray Structure of (OEP)Bi(SO ₃ CF ₃)	211
9.3.2 Other X-ray Structures with Tetra-Mesoaryl Porphyrin: Bi(tpClpp)NO ₃ and Bi(tpClpp)Br	211
9.4 Bismuth Complexes of Functionalized Porphyrins	212
9.4.1 Picket Porphyrins	213
9.4.2 Bis-Strapped Porphyrins	223
9.4.3 Single-Strapped Porphyrins	236
9.5 Future Strategies Towards Bifunctional Chelates (BFC) – Conclusions	237
References	239
10 <i>Helicobacter pylori</i> and Bismuth	241
<i>Aruni H.W. Mendis and Barry J. Marshall</i>	
10.1 Introduction	241
10.2 <i>Helicobacter pylori</i>	243
10.2.1 Disease Associations and Clinical Manifestations	245
10.3 Bismuth as an Antimicrobial Agent	246
10.3.1 Bismuth Subsalicylate (BSS)	246
10.3.2 Colloidal Bismuth Subcitrate (CBS)	249
10.4 Mechanism of Action of Bismuth Citrate and CBS on <i>H. pylori</i> and Ulcer Healing	250
10.4.1 Bismuth Toxicity	253
10.5 <i>In Vitro</i> Susceptibility of <i>H. pylori</i> and other Bacteria to Bismuth Compounds and Antibiotics	253
10.6 The Effect of pH on Bactericidal Activity of Bismuth Compounds	254
10.7 Novel Preparations of Bismuth Compounds	255
10.8 Novel Delivery Systems for Bismuth Compounds and Other Antibiotics	255
10.9 The Biochemical Targets of Bismuth	256
10.9.1 Enzymes with Zn(II) and Fe(III) Sites	256
10.9.2 Heat Shock Proteins	256
10.9.3 Other Metabolic Enzymes	257
10.9.4 Fumarase and Translational Factor Ef-Tu	257
10.9.5 Phospholipases	257
10.9.6 Pepsin	257
10.9.7 Alcohol Dehydrogenase	258
10.9.8 Urease	258
10.10 Binding of Bismuth Compounds to Plasma Proteins	258
References	259

11 Application of Arsenic Trioxide Therapy for Patients with Leukaemia	263
<i>Bo Yuan, Yuta Yoshino, Toshikazu Kaise and Hiroo Toyoda</i>	
11.1 Introduction	263
11.2 Cellular and Molecular Mechanisms of ATO Actions	264
11.2.1 History of Arsenic as a Drug	264
11.2.2 Uptake of Arsenic	265
11.2.3 Efflux of Arsenic	266
11.2.4 Apoptosis Induction	267
11.2.5 Differentiation Induction	273
11.2.6 Degradation of PML-RAR α	274
11.2.7 Proliferation Inhibition and Angiogenesis Inhibition	275
11.3 Pharmacokinetics of ATO in APL Patients	276
11.3.1 Administration Route and Distribution	276
11.3.2 Metabolism and Pharmacokinetics	277
11.3.3 Adverse Effects and Biological Monitoring	280
11.4 Potential Combination Therapies with ATO	281
11.4.1 Natural Product Derived Substances	281
11.4.2 Cytokine	282
11.4.3 Other Reagents	283
11.5 Potential ATO Application to Other Leukaemias	284
11.6 Conclusion	285
Acknowledgements	286
References	286
12 Anticancer Activity of Molecular Compounds of Arsenic, Antimony and Bismuth	293
<i>Edward R.T. Tiekink</i>	
12.1 Introduction	293
12.2 Arsenic Compounds	295
12.3 Antimony Compounds	298
12.4 Bismuth Compounds	303
12.5 Conclusions	307
References	307
13 Radiobismuth for Therapy	311
<i>Martin W. Brechbiel and Ekaterina Dadachova</i>	
13.1 Introduction	311
13.2 Targeting Vectors	312
13.3 α -Emitters versus β^- -Emitters	313
13.4 Radionuclides	313
13.4.1 ^{212}Bi	314
13.4.2 ^{213}Bi	315

13.5	Radiolabeling – Chemistry	315
13.6	Preclinical Studies	317
13.6.1	^{212}Bi	317
13.6.2	^{213}Bi	317
13.7	Targeted α -Therapy versus Targeted β -Therapy	321
13.8	Clinical Studies	322
13.8.1	^{213}Bi	322
13.9	Alternate Delivery Methods and Uses	323
13.10	Prospects and Conclusions	324
	Abbreviations	326
	Acknowledgements	326
	References	326
14	Genetic Toxicology of Arsenic and Antimony	331
	<i>Toby G. Rossman and Catherine B. Klein</i>	
14.1	Introduction	331
14.2	DNA Damage in Cells Treated with Arsenicals	332
14.3	Mutagenesis in Cells Treated with Arsenicals	333
14.4	Other Genotoxic Events in Cells Treated with Arsenicals	335
14.5	Effects of Arsenicals on DNA Repair	337
14.6	Indirect Mechanisms of Mutagenicity and Comutagenicity by Arsenicals	339
14.7	Mutagenesis and Transformation as Secondary Effects of Genomic Instability	340
14.8	Antimony	344
	References	345
15	Metalloproteomics of Arsenic, Antimony and Bismuth Based Drugs	353
	<i>Cheuk-Nam Tsang, Ruiguang Ge and Hongzhe Sun</i>	
15.1	Introduction	353
15.2	Chemical Speciation of Arsenic Based Drugs and their Metallometabolism	355
15.2.1	Metallometabolism in Biological Matrices	355
15.2.2	Arsenic Metabolism	355
15.3	Metalloproteomics and its Applications to As-, Sb- and Bi-Based Metallodrugs	356
15.3.1	From Proteomics to Metalloproteomics	356
15.3.2	Metal Specific Selection, Detection and Prediction Methods in Metalloproteomics	357
15.3.3	Identification of Potential Targets of As-, Sb-, and Bi-Based Drugs by Metalloproteomics	364

15.4	Biological Regulation of Arsenic and Antimony	366
15.4.1	Arsenic and Antimony Uptake Systems	366
15.4.2	Arsenic and Antimony Extrusion Systems	369
15.5	Conclusions	370
	Acknowledgements	371
	References	371
	<i>Index</i>	377